AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
100_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Assets_NN
pledged_VBD [SUAV]
Mortgages_NN
and_CC
other_JJ
assets_NN
pledged_VBD [SUAV]
90_CD
118_CD
Commitments_NOMZ
Contracts_NN
placed_VBN [WZPAST]
for_PIN
future_JJ
capital_NN
expenditure_NN
not_XX0
provided_VBN
for_PIN
in_PIN
these_DEMO
accounts_NN
421 500 515_CD
Included_VBN
in_PIN
the_DT
above_PLACE
total_NN
are_VPRT [PASS]
contracts_NN
related_VBN [WZPAST]
to_PIN
certain_JJ
product_NN
purchase_NN
and_PHC
licence_NN
agreements_NOMZ
with_PIN
deferred_JJ
consideration_NOMZ
obligations_NOMZ
,_,
the_DT
amounts_NN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
variable_PRED
depending_VBG
upon_PIN
particular_JJ
milestone_NN
achievements_NOMZ
._.
Sales_NN
of_PIN
the_DT
products_NN
to_PIN
which_WDT [PIRE]
these_DEMO
milestones_NN
relate_VPRT
could_POMD
give_VB
rise_VB
to_PIN
additional_JJ
payments_NOMZ
,_,
contingent_NN
upon_PIN
the_DT
sales_NN
levels_NN
achieved_VBN
._.
Guarantees_NN
and_PHC
contingencies_NN
arising_VBG [WZPRES]
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
for_PIN
which_WDT [PIRE]
no_SYNE
security_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
given_VBN
,_,
are_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
any_QUAN
material_NN
financial_JJ
loss_NN
._.
Commitments_NOMZ
In_PIN
1982_CD
Astra_NN
AB_NN
set_VBD
up_RP
a_DT
joint_JJ
venture_NN
with_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
for_PIN
the_DT
purposes_NN
of_PIN
selling_GER
,_,
marketing_GER
and_CC
distributing_VBG
certain_JJ
Astra_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
1998_CD
,_,
this_DEMO
joint_JJ
venture_NN
was_VBD [PASS]
restructured_VBN
the_DT
restructuring_GER
._.
Under_IN
the_DT
restructuring_GER
,_,
a_DT
US_FPP1
limited_JJ
partnership_NN
,_,
in_PIN
which_WDT [PIRE]
Merck_NN
is_VPRT [BEMA]
the_DT
limited_JJ
partner_NN
and_PHC
AstraZeneca_NN
is_VPRT [BEMA]
the_DT
general_JJ
partner_NN
,_,
was_VBD [PASS]
set_VBN
up_RP
and_CC
AstraZeneca_NN
obtained_VBD
control_NN
of_PIN
the_DT
joint_JJ
ventures_NN
business_NOMZ
subject_NN
to_PIN
certain_JJ
limited_JJ
partner_NN
and_CC
other_JJ
rights_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Merck_NN
and_CC
its_PIT
affiliates_NN
._.
The_DT
restructuring_GER
agreements_NOMZ
provide_VPRT
for_PIN
the_DT
following_VBG
ongoing_JJ
payment_NOMZ
and_PHC
termination_NOMZ
arrangements_NOMZ
:_:
Annual_JJ
contingent_JJ
payments_NOMZ
Partial_NN
Redemption_NOMZ
First_NN
Option_NOMZ
Second_JJ
Option_NOMZ
In_CONJ
addition_NULL
,_,
included_VBD
in_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
covered_VBN [WZPAST]
by_PIN
the_DT
restructuring_GER
is_VPRT [BEMA]
a_DT
loan_NN
note_NN
receivable_NN
by_PIN
AstraZeneca_NN
from_PIN
Merck_NN
with_PIN
a_DT
face_NN
value_NN
of_PIN
$_$
1.4_CD
bn_NN
._.
Each_QUAN
of_PIN
these_DEMO
elements_NOMZ
is_VPRT [PASS]
discussed_VBN
in_PIN
further_JJ
detail_NN
below_PLACE
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
1998_CD
restructuring_GER
,_,
the_DT
merger_NN
in_PIN
1999_CD
between_PIN
Astra_NN
and_PHC
Zeneca_NN
triggered_VBD
two_CD
one-time_JJ
payments_NOMZ
from_PIN
AstraZeneca_NN
to_PIN
Merck_NN
:_:
a_DT
Lump_NN
Sum_NN
Payment_NOMZ
of_PIN
$_$
809m_CD
,_,
which_WDT [SERE]
was_VBD [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
which_WDT [PIRE]
Merck_NN
relinquished_VBD
any_QUAN
rights_NN
to_PIN
Zeneca_NN
products_NN
:_:
and_ANDC
an_DT
Advance_NN
Payment_NOMZ
of_PIN
$_$
967m_CD
._.
This_DEMO
Advance_NN
Payment_NOMZ
was_VBD [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
then_RB
net_JJ
present_JJ
value_NN
of_PIN
$_$
2.8_CD
bn_NN
discounted_VBN [WZPAST]
from_PIN
2008_CD
to_PIN
the_DT
date_NN
of_PIN
payment_NOMZ
at_PIN
a_DT
rate_NN
of_PIN
13_CD
%_NN
per_PIN
annum_NN
and_CC
causes_VPRT
Merck_NN
to_TO
relinquish_VB
any_QUAN
rights_NN
,_,
including_VBG
contingent_JJ
payments_NOMZ
on_PIN
future_JJ
sales_NN
,_,
to_PIN
Astra_NN
products_NN
with_PIN
no_DT
existing_VBG
or_CC
pending_VBG
US_FPP1
patents_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
._.
As_IN
the_DT
Advance_NN
Payment_NOMZ
provides_VPRT
AstraZeneca_NN
with_PIN
relief_NN
from_PIN
future_JJ
payments_NOMZ
,_,
this_DEMO
amount_NN
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
as_IN
an_DT
intangible_JJ
asset_NN
and_CC
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
20_CD
years_NN
._.
The_DT
Advance_NN
Payment_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
true-up_NN
in_PIN
2008_CD
,_,
as_IN
discussed_VBN
under_IN
First_NN
Option_NOMZ
below_PLACE
._.
Annual_JJ
contingent_JJ
payments_NOMZ
AstraZeneca_NN
makes_VPRT
ongoing_JJ
payments_NOMZ
to_PIN
Merck_NN
based_VBN [WZPAST]
on_PIN
sales_NN
of_PIN
certain_JJ
of_PIN
its_PIT
products_NN
in_PIN
the_DT
US_FPP1
the_DT
contingent_JJ
payments_NOMZ
on_PIN
the_DT
agreement_NOMZ
products_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
1999_CD
merger_NN
,_,
these_DEMO
contingent_JJ
payments_NOMZ
excluding_VBG [WZPRES]
those_DEMO
in_PIN
respect_NN
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
can_POMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
annual_JJ
minimum_NN
sums_NN
between_PIN
2002_CD
and_CC
2007_CD
ranging_VBG
from_PIN
$_$
125m_CD
to_TO
$_$
225m_CD
._.
The_DT
payments_NOMZ
have_VPRT [PEAS]
exceeded_VBN
the_DT
minimum_JJ
level_NN
in_PIN
2003_CD
and_CC
2002_CD
and_CC
AstraZeneca_NN
has_VPRT
no_SYNE
reason_NN
to_TO
believe_VB [PRIV]
that_THVC
the_DT
annual_JJ
payments_NOMZ
in_PIN
the_DT
future_NN
will_PRMD
fall_VB
below_PLACE
the_DT
minimum_NN
obligations_NOMZ
._.
Partial_JJ
Redemption_NOMZ
In_PIN
2008_CD
,_,
there_EX
will_PRMD
be_VB
a_DT
partial_JJ
redemption_NOMZ
of_PIN
Mercks_NN
limited_JJ
partnership_NN
interest_NN
which_WDT [WHSUB]
will_PRMD
end_VB
Mercks_NN
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
certain_JJ
of_PIN
the_DT
agreement_NOMZ
products_NN
by_PIN
distribution_NOMZ
to_PIN
Merck_NN
of_PIN
an_DT
amount_NN
calculated_VBN [PRIV]
as_IN
a_DT
multiple_NN
of_PIN
the_DT
average_JJ
annual_JJ
contingent_JJ
payments_NOMZ
from_PIN
2005_CD
to_PIN
2007_CD
on_PIN
the_DT
relevant_JJ
products_NN
,_,
plus_PIN
$_$
750m_CD
._.
First_NN
Option_NOMZ
In_PIN
2008_CD
,_,
a_DT
calculation_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
Appraised_NN
Value_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
net_JJ
present_JJ
value_NN
of_PIN
the_DT
future_JJ
contingent_JJ
payments_NOMZ
in_PIN
respect_NN
of_PIN
all_QUAN
agreement_NOMZ
products_NN
not_XX0
covered_VBN
by_PIN
the_DT
Partial_NN
Redemption_NOMZ
,_,
other_JJ
than_PIN
Prilosec_NN
and_PHC
Nexium_NN
._.
Payment_NOMZ
of_PIN
this_DEMO
amount_NN
to_PIN
Merck_NN
in_PIN
2008_CD
is_VPRT
,_,
however_CONJ
,_,
contingent_NN
on_PIN
Mercks_NN
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
._.
Exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
will_PRMD
require_VB [SUAV]
AstraZeneca_NN
to_TO
re-purchase_VB
Mercks_NN
interest_NN
in_PIN
these_DEMO
products_NN
._.
Should_NEMD
Merck_NN
not_XX0
exercise_VB
this_DEMO
option_NOMZ
in_PIN
2008_CD
,_,
AstraZeneca_NN
may_POMD
exercise_VB
it_PIT
in_PIN
2010_CD
for_PIN
a_DT
sum_NN
equal_JJ
to_PIN
the_DT
2008_CD
Appraised_NN
Value_NN
._.
If_COND
neither_SYNE
Merck_NN
nor_SYNE
AstraZeneca_NN
exercise_VPRT
the_DT
option_NOMZ
,_,
the_DT
contingent_JJ
payment_NOMZ
arrangements_NOMZ
in_PIN
respect_NN
of_PIN
these_DEMO
agreement_NOMZ
products_NN
will_PRMD
continue_VB
and_CC
the_DT
Appraised_NN
Value_NN
will_PRMD
not_XX0
be_VB [PASS]
paid_VBN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
101_CD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
In_CONJ
addition_NULL
,_,
in_PIN
2008_CD
there_EX
will_PRMD
be_VB
a_DT
true-up_NN
of_PIN
the_DT
Advance_NN
Payment_NOMZ
._.
The_DT
calculation_NOMZ
of_PIN
this_DEMP
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
a_DT
multiple_NN
of_PIN
the_DT
average_JJ
annual_JJ
contingent_JJ
payments_NOMZ
from_PIN
2005_CD
to_PIN
2007_CD
in_PIN
respect_NN
of_PIN
all_QUAN
the_DT
agreement_NOMZ
products_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
Prilosec_NN
and_PHC
Nexium_NN
subject_JJ
to_PIN
a_DT
minimum_NN
of_PIN
$_$
6.6_CD
bn_NN
,_,
plus_PIN
other_JJ
defined_VBN
amounts_NN
totalling_VBG [WZPRES]
$_$
912m_CD
._.
It_PIT
is_VPRT [SPAU] [BYPA]
then_RB
reduced_VBN
by_PIN
the_DT
Appraised_NN
Value_NN
whether_IN
paid_VBN
or_CC
not_XX0
,_,
the_DT
Partial_NN
Redemption_NOMZ
and_CC
the_DT
Advance_NN
Payment_NOMZ
at_PIN
its_PIT
undiscounted_JJ
amount_NN
of_PIN
$_$
2.8_CD
bn_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
true-up_JJ
amount_NN
._.
The_DT
true-up_NN
will_PRMD
be_VB [PASS]
settled_VBN
in_PIN
2008_CD
irrespective_RB
of_PIN
whether_IN
the_DT
First_NN
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
and_CC
this_DEMP
could_POMD
result_VB
in_PIN
a_DT
further_JJ
payment_NOMZ
by_PIN
AstraZeneca_NN
to_PIN
Merck_NN
or_CC
a_DT
payment_NOMZ
by_PIN
Merck_NN
to_PIN
AstraZeneca_NN
._.
Should_NEMD
Merck_NN
exercise_NN
the_DT
First_NN
Option_NOMZ
in_PIN
2008_CD
,_,
AstraZeneca_NN
will_PRMD
make_VB
payments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
Partial_NN
Redemption_NOMZ
,_,
the_DT
First_NN
Option_NOMZ
and_CC
the_DT
true-up_JJ
totalling_VBG
a_DT
minimum_NN
of_PIN
$_$
4.7_CD
bn_NN
._.
If_COND
AstraZeneca_NN
exercises_VPRT
the_DT
First_NN
Option_NOMZ
in_PIN
2010_CD
,_,
the_DT
combined_VBN
effect_NN
will_PRMD
involve_VB
a_DT
minimum_JJ
aggregate_JJ
amount_NN
payable_JJ
to_PIN
Merck_NN
in_PIN
2008_CD
and_CC
2010_CD
of_PIN
the_DT
same_JJ
amount_NN
._.
Loan_NN
Note_NN
Receivable_NN
In_PIN
2008_CD
,_,
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
settlement_NOMZ
of_PIN
the_DT
Partial_NN
Redemption_NOMZ
and_CC
the_DT
true-up_NN
,_,
Merck_NN
will_PRMD
settle_VB
the_DT
loan_NN
note_NN
receivable_NN
by_PIN
paying_VBG
AstraZeneca_NN
$_$
1.4_CD
bn_NN
._.
Second_JJ
Option_NOMZ
A_DT
Second_JJ
Option_NOMZ
exists_VPRT
whereby_OSUB
AstraZeneca_NN
has_VPRT
the_DT
option_NOMZ
to_TO
re-purchase_VB
Mercks_NN
interests_NN
in_PIN
Prilosec_NN
and_PHC
Nexium_NN
in_PIN
the_DT
US_FPP1
._.
This_DEMO
option_NOMZ
is_VPRT [BEMA]
exercisable_PRED
by_PIN
AstraZeneca_NN
two_CD
years_NN
after_IN
the_DT
exercise_NN
of_PIN
the_DT
First_NN
Option_NOMZ
,_,
whether_IN
the_DT
First_NN
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
in_PIN
either_DT
2008_CD
or_CC
2010_CD
._.
Exercise_NN
of_PIN
the_DT
Second_JJ
Option_NOMZ
by_PIN
AstraZeneca_NN
at_PIN
a_DT
later_TIME
date_NN
is_VPRT [SPAU] [PASS]
also_RB
provided_VBN
for_PIN
in_PIN
2017_CD
or_CC
if_COND
combined_VBN
annual_JJ
sales_NN
of_PIN
the_DT
two_CD
products_NN
fall_VPRT
below_PLACE
a_DT
minimum_JJ
amount_NN
provided_VBN
,_,
in_PIN
each_QUAN
case_NN
,_,
that_THVC
the_DT
First_NN
Option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
exercised_VBN
._.
The_DT
exercise_NN
price_NN
for_PIN
the_DT
Second_JJ
Option_NOMZ
is_VPRT [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
product_NN
rights_NN
as_IN
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
time_NN
of_PIN
exercise_NN
._.
If_COND
the_DT
Second_JJ
Option_NOMZ
is_VPRT [PASS]
exercised_VBN
,_,
Merck_NN
will_PRMD
have_VB
no_SYNE
further_JJ
rights_NN
to_PIN
contingent_JJ
payments_NOMZ
from_PIN
AstraZeneca_NN
._.
Environmental_JJ
costs_NN
and_PHC
liabilities_NOMZ
The_DT
Groups_NN
expenditure_NN
on_PIN
environmental_JJ
protection_NOMZ
,_,
including_VBG [PRESP]
both_DT
capital_NN
and_PHC
revenue_NN
items_NN
,_,
relates_VPRT
to_PIN
costs_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
necessary_PRED
for_PIN
meeting_VBG
current_JJ
good_JJ
practice_NN
standards_NN
and_CC
legal_JJ
and_PHC
regulatory_JJ
requirements_NOMZ
for_PIN
processes_NN
and_PHC
products_NN
._.
They_TPP3
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
normal_JJ
ongoing_JJ
expenditure_NN
for_PIN
maintaining_VBG [PUBV]
the_DT
Groups_NN
R&D_NN
and_CC
manufacturing_VBG
capacity_NOMZ
and_PHC
product_NN
ranges_NN
and_CC
are_VPRT [PASS]
not_XX0
separated_VBN
from_PIN
overall_JJ
operating_GER
and_PHC
development_NOMZ
costs_NN
._.
There_EX
are_VPRT
no_DT
known_VBN [PRIV]
changes_NN
in_PIN
legal_JJ
,_,
regulatory_JJ
or_CC
other_JJ
requirements_NOMZ
resulting_VBG [WZPRES]
in_PIN
material_NN
changes_NN
to_PIN
the_DT
levels_NN
of_PIN
expenditure_NN
for_PIN
2001_CD
,_,
2002_CD
or_CC
2003_CD
._.
In_CONJ
addition_NULL
to_PIN
expenditure_NN
for_PIN
meeting_GER
current_JJ
and_CC
foreseen_VBN
environmental_JJ
protection_NOMZ
requirements_NOMZ
,_,
the_DT
Group_NN
incurs_VPRT
substantial_JJ
costs_NN
in_PIN
investigating_VBG
and_PHC
cleaning_VBG
up_RP
land_NN
and_PHC
groundwater_NN
contamination_NOMZ
._.
In_CONJ
particular_NULL
,_,
AstraZeneca_NN
and_CC
or_CC
its_PIT
affiliates_NN
have_VPRT
environmental_JJ
liabilities_NOMZ
at_PIN
some_QUAN
currently_RB
or_CC
formerly_TIME
owned_VBN
,_,
leased_VBN
and_CC
third_JJ
party_NN
sites_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
._.
In_PIN
the_DT
US_FPP1
,_,
the_DT
AstraZeneca_NN
affiliate_NN
,_,
Zeneca_NN
Inc._NN
and_CC
or_CC
its_PIT
indemnitees_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
potentially_RB
responsible_JJ
parties_NN
PRPS_NN
or_CC
defendants_NN
at_PIN
approximately_RB
13_CD
sites_NN
where_RB
Zeneca_NN
Inc._NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
future_JJ
investigation_NOMZ
,_,
remediation_NOMZ
or_CC
operation_NOMZ
and_PHC
maintenance_NN
costs_NN
under_IN
federal_JJ
or_CC
state_NN
,_,
statutory_JJ
or_CC
common_JJ
law_NN
environmental_JJ
liability_NOMZ
allocations_NOMZ
schemes_NN
._.
Similarly_CONJ
,_,
the_DT
AstraZeneca_NN
affiliate_NN
,_,
Stauffer_NN
Management_NOMZ
Company_NN
LLC_NN
SMC_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
established_VBN [PRIV]
in_PIN
1987_CD
to_TO
own_VB
and_PHC
manage_VB
certain_JJ
assets_NN
of_PIN
Stauffer_NN
Chemical_NN
Company_NN
acquired_VBD
that_DEMO
year_NN
,_,
and_ANDC
or_CC
its_PIT
indemnitees_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
PRPS_NN
or_CC
defendants_NN
at_PIN
approximately_RB
29_CD
sites_NN
where_RB
SMC_NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
future_JJ
investigation_NOMZ
,_,
remediation_NOMZ
or_CC
operation_NOMZ
and_PHC
maintenance_NN
costs_NN
under_IN
federal_JJ
or_CC
state_NN
,_,
statutory_JJ
or_CC
common_JJ
law_NN
environmental_JJ
liability_NOMZ
allocations_NOMZ
schemes_NN
._.
In_PIN
Europe_NN
and_CC
other_JJ
parts_NN
of_PIN
the_DT
world_NN
outside_PLACE
the_DT
US_FPP1
,_,
AstraZeneca_NN
is_VPRT [BEMA]
likely_PRED
to_TO
incur_VB
costs_NN
at_PIN
three_CD
currently_RB
owned_VBN
sites_NN
and_CC
has_VPRT [PEAS]
given_VBN
indemnities_NOMZ
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
approximately_RB
45_CD
other_JJ
sites_NN
._.
These_DEMO
environmental_JJ
liabilities_NOMZ
arise_VPRT
almost_DWNT
entirely_AMP
from_PIN
legacy_NN
operations_NOMZ
that_TSUB
are_VPRT
not_XX0
part_NN
of_PIN
our_FPP1
current_JJ
pharmaceuticals_NN
business_NOMZ
and_CC
,_,
at_PIN
most_EMPH
of_PIN
these_DEMO
sites_NN
,_,
remediation_NOMZ
,_,
where_RB
required_VBN [SUAV]
,_,
is_VPRT [SPAU] [PASS]
either_RB
completed_VBN
or_CC
nearing_VBG
completion_NOMZ
._.
In_PIN
the_DT
aggregate_NN
,_,
however_CONJ
,_,
significant_JJ
expenditure_NN
on_PIN
clean_JJ
up_RB
and_CC
monitoring_GER
is_VPRT [BEMA]
likely_PRED
to_TO
be_VB [PASS]
required_VBN [SUAV]
._.
We_FPP1
have_VPRT [PEAS]
made_VBN
provisions_NN
for_PIN
the_DT
estimated_VBN [PRIV]
costs_NN
of_PIN
future_JJ
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_PHC
operation_NOMZ
and_PHC
maintenance_NN
activity_NOMZ
beyond_IN
normal_JJ
ongoing_JJ
expenditure_NN
for_PIN
maintaining_VBG [PUBV]
the_DT
Groups_NN
R&D_NN
and_CC
manufacturing_VBG
capacity_NOMZ
and_PHC
product_NN
ranges_NN
where_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
we_FPP1
will_PRMD
incur_VB
such_JJ
costs_NN
and_CC
we_FPP1
can_POMD
estimate_VB [PRIV]
such_JJ
costs_NN
reliably_RB
._.
With_PIN
respect_NN
to_PIN
such_JJ
estimated_VBN [PRIV]
,_,
future_JJ
costs_NN
,_,
we_FPP1
had_VBD
provisions_NN
at_PIN
31_CD
December_NN
2003_CD
in_PIN
the_DT
aggregate_NN
of_PIN
approximately_RB
$_$
145m_CD
,_,
of_PIN
which_WDT [PIRE]
approximately_RB
$_$
122m_CD
relates_VPRT
to_PIN
the_DT
US_FPP1
._.
These_DEMO
provisions_NN
do_VPRT
not_XX0
include_VB
possible_JJ
,_,
additional_JJ
costs_NN
that_TSUB
are_VPRT
not_XX0
currently_RB
probable_PRED
,_,
nor_SYNE
do_VB
these_DEMO
provisions_NN
include_VPRT
costs_NN
that_DEMP
,_,
by_PIN
agreement_NOMZ
,_,
will_PRMD
be_VB [BYPA]
borne_VBN
by_PIN
viable_JJ
third_JJ
party_NN
indemnitors_NN
._.
In_CONJ
addition_NULL
,_,
these_DEMO
provisions_NN
:_:
1_CD
include_VPRT
,_,
where_RB
appropriate_JJ
,_,
unasserted_JJ
claims_NN
where_RB
future_JJ
costs_NN
are_VPRT [BEMA]
nonetheless_CONJ
probable_PRED
at_PIN
owned_VBN
sites_NN
,_,
for_CONJ
example_NULL
:_:
2_CD
are_VPRT [PASS]
based_VBN
,_,
where_RB
applicable_JJ
,_,
on_PIN
liability_NOMZ
allocation_NOMZ
or_CC
cost_NN
sharing_GER
agreements_NOMZ
that_TOBJ
we_FPP1
believe_VPRT [PRIV]
are_VPRT [BEMA]
enforceable_PRED
against_PIN
viable_JJ
third_JJ
parties_NN
:_:
3_CD
reflect_VPRT [PRIV]
expected_VBN [PRIV]
insurance_NN
recoveries_NN
where_RB
an_DT
insurer_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
provide_VB
an_DT
indemnity_NOMZ
:_:
and_ANDC
4_CD
typically_RB
cover_VPRT
a_DT
time_NN
period_NN
of_PIN
five_CD
years_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
operation_NOMZ
and_PHC
maintenance_NN
activity_NOMZ
,_,
which_WDT [SERE]
can_POMD
last_VB
for_PIN
decades_NN
._.
We_FPP1
are_VPRT
not_XX0
presently_TIME
aware_PRED
of_PIN
any_QUAN
circumstances_NN
or_CC
uncertainties_NN
regarding_VBG [WZPRES]
the_DT
viability_NOMZ
of_PIN
liable_JJ
third_JJ
parties_NN
,_,
indemnitors_NN
or_CC
insurers_NN
that_TSUB
would_PRMD
cause_VB
us_FPP1
to_TO
alter_VB
these_DEMO
provisions_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
102_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
It_PIT
is_VPRT [BEMA]
possible_PRED
that_THAC
the_DT
Company_NN
,_,
or_CC
its_PIT
affiliates_NN
,_,
could_POMD
incur_VB
future_JJ
environmental_JJ
costs_NN
beyond_IN
the_DT
extent_NN
of_PIN
our_FPP1
current_JJ
provisions_NN
._.
The_DT
extent_NN
of_PIN
such_JJ
possible_JJ
,_,
additional_JJ
costs_NN
is_VPRT [BEMA]
inherently_RB
difficult_PRED
to_TO
estimate_VB [PRIV]
due_JJ
to_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
:_:
1_CD
the_DT
nature_NN
and_PHC
extent_NN
of_PIN
claims_NN
that_TSUB
may_POMD
be_VB [PASS]
asserted_VBN [PUBV]
in_PIN
the_DT
future_NN
:_:
2_CD
whether_IN
the_DT
Company_NN
or_CC
any_QUAN
of_PIN
its_PIT
affiliates_NN
has_VPRT
or_CC
will_PRMD
have_VB
any_QUAN
legal_JJ
obligation_NOMZ
with_PIN
respect_NN
to_TO
asserted_VBD [PUBV]
or_CC
unasserted_JJ
claims_NN
:_:
3_CD
the_DT
type_NN
of_PIN
remedial_JJ
action_NOMZ
,_,
if_COND
any_QUAN
,_,
that_DEMP
may_POMD
be_VB [PASS]
selected_VBN
at_PIN
sites_NN
where_RB
the_DT
remedy_NN
is_VPRT [PASS]
presently_TIME
not_XX0
known_VBN [PRIV]
:_:
4_LS
the_DT
potential_NN
for_PIN
recoveries_NN
from_PIN
or_CC
allocation_NOMZ
of_PIN
liability_NOMZ
to_PIN
third_JJ
parties_NN
:_:
5_CD
the_DT
length_NN
of_PIN
time_NN
that_TOBJ
the_DT
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_PHC
liability_NOMZ
allocation_NOMZ
process_NN
can_POMD
take_VB
:_:
and_ANDC
6_CD
the_DT
nature_NN
of_PIN
any_QUAN
future_JJ
environmental_JJ
legal_JJ
or_CC
regulatory_JJ
changes_NN
that_TSUB
affect_VPRT
the_DT
operation_NOMZ
of_PIN
our_FPP1
pharmaceuticals_NN
business_NOMZ
._.
Notwithstanding_CONJ
and_CC
subject_JJ
to_PIN
the_DT
foregoing_GER
,_,
we_FPP1
estimate_VPRT [PRIV]
that_THVC
potential_JJ
additional_JJ
loss_NN
,_,
for_PIN
future_JJ
environmental_JJ
investigation_NOMZ
,_,
remediation_NOMZ
and_PHC
operation_NOMZ
and_PHC
maintenance_NN
activity_NOMZ
above_PLACE
and_CC
beyond_IN
our_FPP1
provisions_NN
,_,
could_POMD
be_VB
,_,
in_PIN
the_DT
aggregate_NN
,_,
in_PIN
the_DT
order_NN
of_PIN
$_$
30m_CD
to_TO
$_$
50m_CD
._.
Legal_JJ
proceedings_GER
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
businesses_NOMZ
,_,
including_VBG
litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
employment_NOMZ
,_,
product_NN
liability_NOMZ
,_,
commercial_JJ
disputes_NN
,_,
infringement_NOMZ
of_PIN
intellectual_JJ
property_NN
rights_NN
and_CC
the_DT
validity_NOMZ
of_PIN
certain_JJ
patents_NN
._.
The_DT
more_EMPH
significant_JJ
matters_NN
are_VPRT [PASS]
discussed_VBN
below_PLACE
._.
Diprivan_NN
propofol_NN
In_PIN
August_NN
2002_CD
,_,
AstraZeneca_NN
LP_NN
received_VBD
a_DT
letter_NN
from_PIN
ESI_NN
Lederle_NN
,_,
a_DT
division_NN
of_PIN
Wyeth_NN
,_,
informing_VBG
AstraZeneca_NN
of_PIN
Wyeths_NN
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Diprivan_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
covering_VBG [WZPRES]
the_DT
current_JJ
formulation_NOMZ
._.
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Wyeth_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
._.
Through_PIN
a_DT
series_NN
of_PIN
transactions_NOMZ
,_,
the_DT
holder_NN
of_PIN
the_DT
relevant_JJ
abbreviated_JJ
new_JJ
drug_NN
application_NOMZ
and_CC
now_TIME
defendant_NN
in_PIN
AstraZenecas_NN
suit_NN
is_VPRT
Mayne_NN
Pharma_NN
USA_NN
Inc._NN
formerly_TIME
called_VBD
Faulding_GER
Pharmaceutical_NN
Co._NN
._.
Faulding_GER
Mayne_NN
responded_VBD
to_PIN
AstraZenecas_NN
complaint_NN
and_CC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
and_CC
invalidity_NOMZ
._.
Discovery_NN
is_VPRT [PASS]
scheduled_VBN
to_TO
close_VB
in_PIN
June_NN
2004_CD
._.
The_DT
trial_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
held_VBN [PRIV]
no_SYNE
earlier_TIME
than_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2004_CD
._.
Losec_NN
Prilosec_NN
omeprazole_NN
In_PIN
June_NN
1997_CD
,_,
the_DT
German_NN
Federal_NN
Patent_NN
Court_NN
declared_VBD [PUBV]
invalid_JJ
a_DT
previously_TIME
granted_VBN [SUAV]
supplementary_JJ
protection_NOMZ
certificate_NN
which_WDT [WHSUB]
extended_VBD
protection_NOMZ
for_PIN
omeprazole_NN
,_,
the_DT
active_JJ
ingredient_NN
contained_VBN [WZPAST]
in_PIN
Losec_NN
,_,
from_PIN
1999_CD
to_PIN
2003_CD
._.
The_DT
decision_NN
was_VBD [PASS]
appealed_VBN
and_CC
in_PIN
February_NN
2000_CD
,_,
at_PIN
AstraZenecas_NN
request_NN
,_,
the_DT
German_NN
Supreme_NN
Court_NN
decided_VBD [SUAV] [PRIV]
to_TO
refer_VB
the_DT
case_NN
to_PIN
the_DT
European_NN
Court_NN
of_PIN
Justice_NN
ECJ_NN
for_PIN
a_DT
preliminary_JJ
ruling_NN
._.
In_PIN
December_NN
2003_CD
,_,
the_DT
ECJ_NN
ruled_VBD [SUAV]
against_PIN
AstraZeneca_NN
on_PIN
all_QUAN
questions_NOMZ
._.
Consequently_CONJ
,_,
the_DT
German_JJ
omeprazole_NN
supplementary_JJ
protection_NOMZ
certificate_NN
is_VPRT [PASS]
confirmed_VBN [PUBV]
invalid_JJ
._.
The_DT
case_NN
did_VBD
not_XX0
involve_VB
any_QUAN
financial_JJ
claims_NN
._.
In_PIN
March_NN
2000_CD
,_,
the_DT
German_NN
Federal_NN
Patent_NN
Court_NN
declared_VBD [PUBV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
for_PIN
omeprazole_NN
was_VBD [BEMA]
invalid_PRED
._.
The_DT
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
appealed_VBN
to_PIN
the_DT
German_JJ
Supreme_NN
Court_NN
,_,
which_WDT [SERE]
will_PRMD
hear_VB [PRIV]
the_DT
case_NN
in_PIN
March_NN
2004_CD
._.
As_CONJ
a_NULL
consequence_NULL
,_,
all_QUAN
pending_VBG
infringement_NOMZ
actions_NOMZ
in_PIN
Germany_NN
have_VPRT [PEAS]
been_VBN [PASS]
stayed_VBN
awaiting_VBG
the_DT
outcome_NN
of_PIN
the_DT
appeal_NN
._.
There_EX
is_VPRT
one_CD
interlocutory_NN
injunction_NOMZ
in_PIN
force_NN
against_PIN
ratiopharm_JJ
GmbH_NN
based_VBN [WZPAST]
on_PIN
the_DT
formulation_NOMZ
patent_NN
._.
If_COND
the_DT
final_JJ
decision_NN
on_PIN
the_DT
validity_NOMZ
of_PIN
the_DT
formulation_NOMZ
patent_NN
goes_VPRT
against_PIN
AstraZeneca_NN
,_,
ratiopharm_NN
may_POMD
claim_VB [PUBV]
damages_NN
for_PIN
lost_VBN
sales_NN
due_JJ
to_PIN
the_DT
interlocutory_JJ
injunction_NOMZ
._.
In_PIN
1998_CD
,_,
Astra_NN
filed_VBD
suits_NN
in_PIN
the_DT
US_FPP1
against_PIN
Andrx_NN
Pharmaceuticals_NN
,_,
Inc._NN
and_PHC
Genpharm_NN
,_,
Inc._NN
._.
This_DEMP
followed_VBD
the_DT
filing_NN
of_PIN
abbreviated_JJ
new_JJ
drug_NN
applications_NOMZ
by_PIN
Andrx_NN
and_PHC
Genpharm_NN
with_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
concerning_VBG [WZPRES]
the_DT
two_CD
companies_NN
intention_NOMZ
to_PIN
market_NN
generic_JJ
omeprazole_NN
products_NN
in_PIN
the_DT
US_FPP1
._.
During_PIN
1999_CD
,_,
Astra_NN
also_RB
filed_VBD
suits_NN
against_PIN
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
and_PHC
Schwarz_NN
Pharma_NN
,_,
Inc._NN
and_CC
against_PIN
Cheminor_NN
Drugs_NN
Ltd._NN
._.
Reddy-Cheminor_NN
Inc._NN
and_PHC
Schein_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
During_PIN
2000_CD
,_,
AstraZeneca_NN
filed_VBD
further_JJ
suits_NN
against_PIN
Lek_NN
Pharmaceutical_NN
and_PHC
Chemical_NN
Company_NN
d._FW
d._FW
Impax_NN
Laboratories_NN
Inc._NN
._.
Eon_NN
Labs_NN
Manufacturing_GER
Inc._NN
and_PHC
Mylan_NN
Pharmaceuticals_NN
Inc._NN
._.
During_PIN
2001_CD
,_,
AstraZeneca_NN
filed_VBD
further_JJ
suits_NN
against_PIN
Torpharm_NN
,_,
Inc._NN
and_PHC
Zenith_NN
Goldline_NN
Pharmaceuticals_NN
,_,
Inc._NN
now_TIME
known_VBN [PRIV]
as_IN
Ivax_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
The_DT
basis_NN
for_PIN
the_DT
proceedings_GER
is_VPRT
that_DEMO
the_DT
actions_NOMZ
of_PIN
all_QUAN
the_DT
companies_NN
infringe_VPRT
several_QUAN
patents_NN
relating_VBG [WZPRES]
to_TO
omeprazole_VB
Prilosec_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
cases_NN
are_VPRT
proceeding_VBG
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
legislation_NOMZ
._.
Anti-trust_JJ
counterclaims_NN
have_VPRT [PEAS]
been_VBN [BYPA]
filed_VBN
by_PIN
Andrx_NN
,_,
Torpharm_NN
,_,
Impax_NN
,_,
Eon_NN
and_PHC
Lek_NN
._.
The_DT
trial_NN
against_PIN
Andrx_NN
,_,
Genpharm_NN
,_,
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
and_PHC
Cheminor_NN
started_VBD
in_PIN
December_NN
2001_CD
and_CC
ended_VBN
in_PIN
July_NN
2002_CD
._.
In_PIN
October_NN
2002_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
ruled_VBD [SUAV]
that_THVC
two_CD
AstraZeneca_NN
patents_NN
230_CD
and_CC
505_CD
relating_VBG
to_PIN
the_DT
formulation_NOMZ
of_PIN
omeprazole_NN
are_VPRT [BEMA]
valid_PRED
until_IN
2007_CD
,_,
that_THVC
Andrx_NN
,_,
Genpharm_NN
and_PHC
Cheminor_NN
all_QUAN
infringed_VBN
both_DT
patents_NN
but_CC
that_THVC
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
did_VBD
not_XX0
infringe_VB
either_DT
patent_NN
._.
The_DT
court_NN
did_VBD
not_XX0
rule_NN
on_PIN
the_DT
281_CD
patent_NN
relating_VBG [WZPRES]
to_PIN
a_DT
manufacturing_GER
process_NN
for_PIN
omeprazole_JJ
formulations_NOMZ
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
AstraZeneca_NN
has_VPRT [PEAS]
sued_VBN
Andrx_NN
only_DWNT
._.
AstraZeneca_NN
appealed_VBD
the_DT
judgement_NOMZ
with_PIN
regard_NN
to_PIN
noninfringement_NOMZ
and_PHC
Kremers_NN
Urban_NN
Development_NOMZ
Company_NN
,_,
Andrx_NN
,_,
Genpharm_NN
and_PHC
Cheminor_NN
appealed_VBD
the_DT
decision_NN
with_PIN
regard_NN
to_PIN
infringement_NOMZ
and_PHC
validity_NOMZ
of_PIN
the_DT
patents_NN
._.
The_DT
appeal_NN
hearings_GER
took_VBD
place_NN
in_PIN
December_NN
2003_CD
and_CC
the_DT
original_JJ
decision_NN
of_PIN
the_DT
lower_JJ
court_NN
was_VBD [BYPA]
affirmed_VBN [PUBV]
by_PIN
the_DT
appeal_NN
court_NN
in_PIN
all_QUAN
respects_NN
._.
In_PIN
April_NN
2001_CD
,_,
Andrx_NN
filed_VBD
a_DT
case_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
AstraZeneca_NN
,_,
Merck_NN
&_CC
Co._NN
._.
Inc._NN
and_CC
the_DT
FDA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
listing_GER
of_PIN
certain_JJ
patents_NN
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
was_VBD [BEMA]
improper_PRED
and_CC
constituted_VBD
violations_NOMZ
of_PIN
certain_JJ
provisions_NN
of_PIN
the_DT
Sherman_NN
Act_NN
,_,
the_DT
US_FPP1
federal_JJ
anti-trust_JJ
legislation_NOMZ
,_,
and_ANDC
a_DT
state_NN
statute_NN
analogous_JJ
to_PIN
the_DT
federal_JJ
anti-trust_JJ
laws_NN
._.
Andrx_NN
seeks_VPRT
injunctive_JJ
relief_NN
compelling_JJ
the_DT
parties_NN
to_TO
delist_VB
omeprazole-related_JJ
patents_NN
it_PIT
claims_VPRT [PUBV]
were_VBN [SPAU] [PASS]
improperly_RB
listed_VBN
in_PIN
the_DT
Orange_NN
Book_NN
and_CC
prohibiting_VBG
the_DT
defendants_NN
from_PIN
using_VBG
patents_NN
to_TO
delay_VB
the_DT
effective_JJ
date_NN
of_PIN
the_DT
FDAs_NN
approval_NN
of_PIN
Andrxs_NN
ANDA_NN
for_PIN
omeprazole_NN
._.
AstraZeneca_NN
and_PHC
Merck_NN
have_VPRT [PEAS]
filed_VBN
motions_NOMZ
to_TO
dismiss_VB
the_DT
case_NN
,_,
which_WDT [SERE]
are_VPRT
pending_VBG
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
103_CD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
In_PIN
October_NN
2000_CD
,_,
the_DT
Federal_NN
Court_NN
of_PIN
Australia_NN
Full_NN
Court_NN
handed_VBD
down_RP
a_DT
patent_NN
ruling_NN
pertaining_VBG [WZPRES]
to_TO
omeprazole_VB
in_PIN
connection_NOMZ
with_PIN
a_DT
dispute_NN
between_PIN
AstraZeneca_NN
and_CC
the_DT
generic_JJ
company_NN
,_,
Alphapharm_NN
Pty_NN
Ltd._NN
._.
The_DT
court_NN
declared_VBD [PUBV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
was_VBD [BEMA]
invalid_PRED
._.
In_PIN
November_NN
2001_CD
,_,
AstraZeneca_NN
applied_VBD
for_PIN
special_JJ
leave_NN
to_TO
appeal_VB
the_DT
decision_NN
to_PIN
the_DT
High_NN
Court_NN
of_PIN
Australia_NN
and_CC
this_DEMO
application_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
December_NN
2001_CD
._.
The_DT
appeal_NN
was_VBD [BYPA]
heard_VBN [PRIV]
by_PIN
the_DT
High_NN
Court_NN
in_PIN
May_POMD
2002_CD
and_CC
in_PIN
December_NN
2002_CD
the_DT
High_NN
Court_NN
reversed_VBD
the_DT
judgement_NOMZ
of_PIN
the_DT
lower_JJ
court_NN
._.
The_DT
High_NN
Court_NN
ruled_VBD [SUAV]
that_THVC
AstraZenecas_NN
formulation_NOMZ
patent_NN
is_VPRT [BEMA]
valid_PRED
and_CC
that_THVC
the_DT
case_NN
should_NEMD
be_VB [PASS]
returned_VBN
to_PIN
the_DT
lower_JJ
court_NN
for_PIN
determination_NOMZ
of_PIN
the_DT
remaining_VBG
issues_NN
._.
In_PIN
July_NN
2003_CD
,_,
the_DT
case_NN
was_VBD [PASS]
settled_VBN
._.
During_PIN
2000_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
granted_VBN [SUAV] [THATD]
interlocutory_JJ
injunctions_NOMZ
based_VBN [WZPAST]
on_PIN
certain_JJ
of_PIN
AstraZenecas_NN
omeprazole_NN
patents_NN
and_CC
supplementary_JJ
protection_NOMZ
certificates_NN
against_PIN
the_DT
generic_JJ
company_NN
,_,
Scandinavian_NN
AB_NN
Scand_NN
Pharm_NN
,_,
in_PIN
Denmark_NN
and_PHC
Norway_NN
._.
In_PIN
October_NN
2001_CD
,_,
Oslo_NN
City_NOMZ
Court_NN
in_PIN
Norway_NN
found_VBD [PRIV]
that_THVC
Scand_NN
Pharm_NN
had_VBD [PEAS]
infringed_VBN
AstraZenecas_NN
formulation_NOMZ
patent_NN
for_PIN
omeprazole_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
the_DT
court_NN
declared_VBD [PUBV]
AstraZenecas_NN
formulation_NOMZ
patent_NN
valid_JJ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Norwegian_JJ
case_NN
,_,
Scand_NN
Pharm_NN
can_POMD
not_XX0
sell_VB
its_PIT
omeprazole_JJ
product_NN
in_PIN
Norway_NN
._.
Furthermore_CONJ
,_,
it_PIT
is_VPRT [SPAU] [PASS]
also_RB
prevented_VBN
from_PIN
selling_VBG
its_PIT
omeprazole_JJ
product_NN
in_PIN
Denmark_NN
pending_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
the_DT
main_JJ
action_NOMZ
in_PIN
the_DT
Danish_JJ
case_NN
._.
If_COND
the_DT
final_JJ
decisions_NN
in_PIN
these_DEMO
cases_NN
are_VPRT [BEMA]
against_PIN
AstraZeneca_NN
,_,
Scand_NN
Pharm_NN
may_POMD
claim_VB [PUBV]
damages_NN
for_PIN
lost_VBN
sales_NN
due_JJ
to_PIN
the_DT
interlocutory_JJ
injunctions_NOMZ
._.
In_PIN
the_DT
Netherlands_NN
,_,
Pharmachemie_NN
BV_NN
filed_VBD
a_DT
claim_NN
against_PIN
two_CD
AstraZeneca_NN
companies_NN
in_PIN
2002_CD
alleging_VBG [PUBV]
that_THVC
AstraZeneca_NN
had_VBD [PEAS]
misused_VBN
its_PIT
exclusive_JJ
rights_NN
in_PIN
the_DT
Netherlands_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
expiration_NOMZ
date_NN
for_PIN
AstraZenecas_NN
supplementary_JJ
protection_NOMZ
certificate_NN
for_PIN
omeprazole_NN
._.
In_PIN
February_NN
2003_CD
,_,
the_DT
case_NN
was_VBD [BYPA]
withdrawn_VBN
by_PIN
Pharmachemie_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
been_VBN
and_PHC
continues_VPRT
to_TO
be_VB [PASS]
involved_VBN
in_PIN
numerous_JJ
proceedings_GER
in_PIN
Canada_NN
involving_VBG [WZPRES]
Genpharm_NN
,_,
Reddy_NN
Cheminor_NN
,_,
Rhoxalpharma_NN
and_PHC
Apotex_NN
._.
These_DEMO
cases_NN
relate_VPRT
to_TO
omeprazole_VB
capsules_NN
or_CC
omeprazole_NN
magnesium_NN
tablets_NN
and_CC
involve_VB
various_JJ
patents_NN
._.
AstraZeneca_NN
could_POMD [SPAU]
potentially_RB
be_VB [BEMA]
liable_PRED
for_PIN
damages_NN
in_PIN
some_QUAN
cases_NN
._.
However_CONJ
,_,
there_EX
are_VPRT
no_SYNE
financial_JJ
claims_NN
currently_RB
being_VBG [PASS]
made_VBN
against_PIN
AstraZeneca_NN
in_PIN
Canada_NN
in_PIN
any_QUAN
litigation_NOMZ
in_PIN
respect_NN
of_PIN
omeprazole_NN
capsules_NN
or_CC
omeprazole_NN
magnesium_NN
tablets_NN
._.
In_PIN
February_NN
2000_CD
,_,
the_DT
European_JJ
Commission_NN
commenced_VBD
an_DT
investigation_NOMZ
relating_VBG [WZPRES]
to_PIN
certain_JJ
omeprazole_NN
intellectual_JJ
property_NN
rights_NN
,_,
and_ANDC
associated_VBN
regulatory_JJ
and_CC
patent_NN
infringement_NOMZ
litigation_NOMZ
._.
The_DT
investigation_NOMZ
is_VPRT [BEMA]
pursuant_PRED
to_PIN
Article_NN
82_CD
of_PIN
the_DT
EC_NN
Treaty_NN
,_,
which_WDT [SERE]
prohibits_VPRT
an_DT
abuse_NN
of_PIN
a_DT
dominant_JJ
position_NOMZ
._.
The_DT
investigation_NOMZ
was_VBD [BYPA]
precipitated_VBN
by_PIN
a_DT
complaint_NN
by_PIN
a_DT
party_NN
to_PIN
a_DT
number_NN
of_PIN
patent_NN
and_CC
other_JJ
proceedings_GER
involving_VBG [WZPRES]
AstraZeneca_NN
._.
AstraZeneca_NN
has_VPRT
,_,
in_PIN
accordance_NN
with_PIN
its_PIT
corporate_JJ
policy_NN
,_,
co-operated_JJ
with_PIN
the_DT
Commission_NN
._.
In_PIN
July_NN
2003_CD
,_,
the_DT
Commission_NN
served_VBD
a_DT
Statement_NOMZ
of_PIN
Objections_NOMZ
on_PIN
AstraZeneca_NN
,_,
referring_VBG
to_TO
alleged_VBN [PUBV] [THATD]
infringements_NOMZ
regarding_VBG [WZPRES]
the_DT
obtaining_VBG
of_PIN
supplementary_JJ
protection_NOMZ
certificates_NN
for_PIN
omeprazole_NN
in_PIN
certain_JJ
European_JJ
countries_NN
:_:
and_ANDC
regarding_VBG
AstraZenecas_NN
replacement_NOMZ
of_PIN
omeprazole_NN
capsules_NN
by_PIN
omeprazole_NN
MUPS_NN
tablets_NN
and_PHC
withdrawal_NN
of_PIN
capsule_NN
marketing_GER
authorisations_NOMZ
in_PIN
three_CD
European_JJ
countries_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
replied_VBN [PUBV]
fully_AMP
to_PIN
the_DT
Commission_NN
,_,
explaining_VBG [PUBV] [PRESP]
why_RB [WHCL]
its_PIT
actions_NOMZ
were_VBD [BEMA]
in_PIN
AstraZenecas_NN
view_NN
lawful_JJ
._.
The_DT
Commission_NN
is_VPRT
considering_VBG [PRIV]
AstraZenecas_NN
submission_NN
,_,
and_ANDC
an_DT
oral_JJ
hearing_GER
is_VPRT [PASS]
scheduled_VBN
to_TO
take_VB
place_NN
._.
If_COND
,_,
ultimately_RB
,_,
and_ANDC
subject_JJ
to_PIN
any_QUAN
appeals_NN
to_PIN
the_DT
Court_NN
of_PIN
First_NN
Instance_NN
and_CC
the_DT
European_NN
Court_NN
of_PIN
Justice_NN
it_PIT
is_VPRT [PASS]
held_VBN [PRIV]
that_THVC
Article_NN
82_CD
has_VPRT [PEAS]
been_VBN [PASS]
infringed_VBN
,_,
then_RB
there_EX
may_POMD
be_VB
a_DT
liability_NOMZ
to_PIN
fines_NN
and_CC
or_CC
other_JJ
measures_NN
which_WDT [WHSUB]
can_POMD
be_VB [BYPA]
imposed_VBN
by_PIN
the_DT
Commission_NN
._.
There_EX
could_POMD [SPAU]
also_RB
be_VB
liability_NOMZ
for_PIN
alleged_JJ
losses_NN
incurred_VBN [WZPAST]
by_PIN
aggrieved_JJ
third_JJ
parties_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
,_,
at_PIN
the_DT
present_JJ
time_NN
,_,
to_TO
quantify_VB
any_QUAN
such_JJ
liabilities_NOMZ
as_IN
no_SYNE
fines_NN
have_VPRT
to_PIN
date_NN
been_VBN [PASS]
imposed_VBN
and_CC
no_SYNE
claims_NN
for_PIN
damages_NN
have_VPRT [PEAS]
been_VBN [PASS]
received_VBN
._.
Moreover_CONJ
,_,
bearing_VBG [PRESP]
in_PIN
mind_NN
the_DT
timescales_NN
of_PIN
proceedings_GER
,_,
including_VBG
appeals_NN
,_,
there_EX
may_POMD [SPAU]
well_RB
be_VB [BEMA]
a_DT
considerable_JJ
period_NN
before_IN
any_QUAN
such_JJ
liabilities_NOMZ
are_VPRT [SPAU] [PASS]
finally_RB
established_VBN [PRIV]
even_RB
if_COND
,_,
which_WDT [SERE]
is_VPRT [PASS]
denied_VBN [PUBV]
,_,
any_QUAN
such_JJ
liabilities_NOMZ
exist_VPRT
._.
Nolvadex_NN
tamoxifen_NN
AstraZeneca_NN
is_VPRT [BEMA]
a_DT
co-defendant_NN
with_PIN
Barr_NN
Laboratories_NN
,_,
Inc._NN
in_PIN
numerous_JJ
purported_JJ
class_NN
actions_NOMZ
filed_VBN [WZPAST]
in_PIN
federal_JJ
and_CC
state_NN
courts_NN
throughout_PIN
the_DT
US_FPP1
._.
All_QUAN
of_PIN
the_DT
state_NN
court_NN
actions_NOMZ
were_VBD [PASS]
removed_VBN
to_PIN
federal_JJ
court_NN
and_CC
have_VPRT [PEAS]
been_VBN [BEMA]
consolidated_PRED
,_,
along_IN
with_PIN
all_QUAN
of_PIN
the_DT
cases_NN
originally_TIME
filed_VBN
in_PIN
federal_JJ
court_NN
,_,
in_PIN
a_DT
federal_JJ
multi-district_JJ
litigation_NOMZ
proceeding_VBG [WZPRES]
pending_VBG
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
New_NN
York_NN
._.
Some_QUAN
of_PIN
the_DT
cases_NN
were_VBD [BYPA]
filed_VBN
by_PIN
plaintiffs_NN
representing_VBG [WZPRES]
a_DT
putative_JJ
class_NN
of_PIN
consumers_NN
who_WP [WHSUB]
purchased_VBD
tamoxifen_NN
._.
The_DT
other_JJ
cases_NN
were_VBD [PASS]
filed_VBN
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
third_JJ
party_NN
payers_NN
including_VBG [WZPRES]
health_NN
maintenance_NN
organizations_NOMZ
,_,
insurers_NN
and_CC
other_JJ
managed_VBN
care_NN
providers_NN
and_PHC
health_NN
plans_NN
that_TSUB
have_VPRT [PEAS]
reimbursed_VBN
or_CC
otherwise_CONJ
paid_VBN
for_PIN
prescriptions_NOMZ
of_PIN
tamoxifen_NN
._.
The_DT
plaintiffs_NN
allege_VPRT [PUBV]
that_THVC
they_TPP3
paid_VBD
supra-competitive_JJ
and_PHC
monopolistic_JJ
prices_NN
for_PIN
tamoxifen_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
settlement_NOMZ
of_PIN
patent_NN
litigation_NOMZ
between_PIN
Zeneca_NN
and_PHC
Barr_NN
in_PIN
1993_CD
._.
The_DT
plaintiffs_NN
seek_VPRT
injunctive_JJ
relief_NN
,_,
treble_JJ
damages_NN
under_IN
the_DT
anti-trust_JJ
laws_NN
,_,
disgorgement_NOMZ
and_PHC
restitution_NOMZ
._.
In_PIN
April_NN
2002_CD
,_,
AstraZeneca_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
cases_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
cause_NN
of_PIN
action_NOMZ
._.
In_PIN
May_POMD
2003_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
New_NN
York_NN
granted_VBD [SUAV]
AstraZenecas_NN
motion_NOMZ
to_TO
dismiss_VB
._.
The_DT
plaintiffs_NN
have_VPRT [PEAS]
appealed_VBN
the_DT
decision_NN
._.
In_PIN
August_NN
2002_CD
,_,
AstraZenecas_NN
US_FPP1
distribution_NOMZ
agreement_NOMZ
with_PIN
Barr_NN
Laboratories_NN
,_,
Inc._NN
for_PIN
non-branded_JJ
tamoxifen_NN
expired_VBD
,_,
as_IN
did_VBD [PROD]
AstraZenecas_NN
patent_NN
for_PIN
Nolvadex_NN
tamoxifen_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
a_DT
six_CD
month_NN
period_NN
of_PIN
market_NN
exclusivity_NOMZ
,_,
awarded_VBN [PASTP]
by_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
in_PIN
connection_NOMZ
with_PIN
the_DT
successful_JJ
completion_NOMZ
of_PIN
certain_JJ
paediatric_JJ
testing_GER
with_PIN
the_DT
product_NN
,_,
commenced_VBN
._.
Barr_NN
thereafter_RB
commenced_VBD
litigation_NOMZ
against_PIN
the_DT
FDA_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Columbia_NN
,_,
challenging_VBG [PRESP]
the_DT
FDAs_NN
refusal_NN
to_TO
grant_VB [SUAV]
Barr_NN
final_JJ
approval_NN
for_PIN
its_PIT
own_JJ
generic_JJ
tamoxifen_NN
prior_RB
to_PIN
expiration_NOMZ
of_PIN
AstraZenecas_NN
exclusivity_NOMZ
period_NN
._.
Barr_NN
also_RB
declined_VBD
AstraZenecas_NN
offer_NN
to_TO
extend_VB
the_DT
distribution_NOMZ
agreement_NOMZ
through_PIN
the_DT
end_NN
of_PIN
the_DT
exclusivity_NOMZ
period_NN
._.
Therefore_CONJ
,_,
in_PIN
October_NN
2002_CD
,_,
AstraZeneca_NN
began_VBD
shipping_VBG
its_PIT
own_JJ
nonbranded_JJ
tamoxifen_NN
to_PIN
customers_NN
to_TO
ensure_VB [SUAV] [PRIV]
an_DT
uninterrupted_JJ
supply_NN
to_PIN
patients_NN
._.
In_PIN
December_NN
2002_CD
,_,
the_DT
Court_NN
held_VBD [PRIV]
that_THVC
Barr_NN
could_POMD
not_XX0
obtain_VB
final_JJ
FDA_NN
approval_NN
for_PIN
its_PIT
own_JJ
generic_JJ
tamoxifen_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
paediatric_JJ
exclusivity_NOMZ
for_PIN
Nolvadex_NN
._.
In_PIN
January_NN
2003_CD
,_,
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
104_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
Barr_NN
made_VBD
a_DT
claim_NN
that_TOBJ
AstraZeneca_NN
improperly_RB
thwarted_VBD
Barrs_NN
entry_NN
into_PIN
the_DT
tamoxifen_JJ
market_NN
and_CC
caused_VBD
Barr_NN
monetary_JJ
damages_NN
._.
Plendil_NN
felodipine_NN
In_PIN
August_NN
2000_CD
,_,
AstraZeneca_NN
LP_NN
received_VBD
a_DT
letter_NN
from_PIN
Mutual_JJ
Pharmaceutical_NN
Co._NN
._.
Inc._NN
informing_VBG [WZPRES]
AstraZeneca_NN
of_PIN
Mutuals_NN
intention_NOMZ
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
AstraZenecas_NN
Plendil_NN
extended_VBD
release_NN
tablets_NN
felodipine_VPRT
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patent_NN
covering_VBG [WZPRES]
the_DT
extended_JJ
release_NN
formulation_NOMZ
._.
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
Mutual_JJ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
._.
Mutual_JJ
responded_VBD
and_PHC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
and_CC
invalidity_NOMZ
._.
In_PIN
March_NN
2003_CD
,_,
the_DT
District_NN
Court_NN
granted_VBD [SUAV]
summary_NN
judgement_NOMZ
in_PIN
favor_NN
of_PIN
AstraZeneca_NN
as_IN
to_PIN
the_DT
infringement_NOMZ
claim_NN
holding_VBG [PRIV] [WZPRES]
that_THVC
Mutual_JJ
infringed_VBN
AstraZenecas_NN
formulation_NOMZ
patent_NN
._.
In_PIN
August_NN
2003_CD
,_,
the_DT
District_NN
Court_NN
granted_VBD [SUAV]
summary_NN
judgement_NOMZ
in_PIN
favor_NN
of_PIN
AstraZeneca_NN
as_IN
to_PIN
the_DT
validity_NOMZ
claim_NN
holding_VBG [PRIV] [WZPRES]
that_THVC
AstraZenecas_NN
patent_NN
is_VPRT [BEMA]
valid_PRED
._.
Mutual_NN
has_VPRT [PEAS]
filed_VBN
a_DT
notice_NN
of_PIN
appeal_NN
as_IN
to_PIN
both_DT
of_PIN
these_DEMO
decisions_NN
to_PIN
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
Seroquel_NN
quetiapine_NN
fumarate_NN
AstraZeneca_NN
PLC_NN
and_PHC
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
defendants_NN
in_PIN
the_DT
case_NN
of_PIN
Susan_NN
Zehel-Miller_NN
et_FW
al._FW
._.
v._CC
AstraZenaca_NN
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
AstraZenaca_NN
Pharmaceuticals_NN
,_,
LP_NN
-LRB-_-LRB-
sic_JJ
-RRB-_-RRB-
,_,
a_DT
putative_JJ
class_NN
action_NOMZ
suit_NN
filed_VBN [WZPAST]
in_PIN
August_NN
2003_CD
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Middle_NN
District_NN
of_PIN
Florida_NN
._.
The_DT
named_VBN
plaintiffs_NN
are_VPRT
seeking_VBG
damages_NN
and_CC
injunctive_JJ
relief_NN
on_PIN
behalf_NN
of_PIN
a_DT
purported_JJ
class_NN
consisting_VBG [WZPRES]
of_PIN
all_QUAN
persons_NN
in_PIN
the_DT
United_NN
States_NN
who_WP [WHSUB]
purchased_VBD
and_CC
or_CC
used_VBN
Seroquel_NN
._.
Although_CONC
the_DT
scope_NN
of_PIN
the_DT
allegations_NOMZ
in_PIN
the_DT
complaint_NN
is_VPRT [BEMA]
very_AMP
broad_PRED
,_,
the_DT
primary_JJ
focus_NN
appears_VPRT [SMP]
to_TO
be_VB [BEMA]
the_DT
contention_NOMZ
that_TOBJ
the_DT
Company_NN
failed_VBD
to_TO
provide_VB
adequate_JJ
warnings_GER
in_PIN
connection_NOMZ
with_PIN
an_DT
alleged_JJ
association_NOMZ
between_PIN
Seroquel_NN
and_CC
the_DT
onset_NN
of_PIN
diabetes_NN
._.
AstraZeneca_NN
denies_VPRT [PUBV]
the_DT
material_NN
allegations_NOMZ
of_PIN
the_DT
plaintiffs_NN
complaint_NN
and_CC
is_VPRT [SPAU]
vigorously_RB
defending_VBG
the_DT
litigation_NOMZ
._.
Toprol-XL_JJ
metoprolol_NN
succinate_VB
In_PIN
March_NN
2003_CD
,_,
AstraZeneca_NN
LP_NN
received_VBD
a_DT
letter_NN
from_PIN
KV_NN
Pharmaceutical_NN
Company_NN
informing_VBG [WZPRES]
AstraZeneca_NN
of_PIN
KVs_NN
intent_NN
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
Toprol-XL_JJ
tablets_NN
in_PIN
the_DT
200mg_JJ
dosage_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
covering_VBG [WZPRES]
the_DT
substance_NN
and_CC
its_PIT
formulation_NOMZ
,_,
the_DT
latest_JJ
of_PIN
which_WDT [PIRE]
expires_VPRT
in_PIN
March_NN
2008_CD
._.
AstraZeneca_NN
filed_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
KV_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Missouri_NN
._.
KV_NN
responded_VBD
and_PHC
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
and_CC
invalidity_NOMZ
._.
Discovery_NN
is_VPRT [PASS]
scheduled_VBN
to_TO
close_VB
in_PIN
August_NN
2004_CD
._.
The_DT
trial_NN
is_VPRT [PASS]
scheduled_VBN
for_PIN
April_NN
2005_CD
._.
In_PIN
July_NN
2003_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
similar_JJ
letter_NN
from_PIN
KV_NN
with_PIN
respect_NN
to_PIN
the_DT
100mg_JJ
dosage_NN
of_PIN
Toprol-XL_JJ
tablets_NN
._.
AstraZeneca_NN
filed_VBD
another_DT
patent_NN
infringement_NOMZ
complaint_NN
against_PIN
KV_NN
in_PIN
the_DT
same_JJ
court_NN
._.
KV_NN
filed_VBD
counterclaims_NN
alleging_VBG [PUBV] [WZPRES]
non-infringement_JJ
and_CC
invalidity_NOMZ
._.
This_DEMO
case_NN
has_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
the_DT
initial_JJ
case_NN
._.
In_PIN
December_NN
2003_CD
,_,
AstraZeneca_NN
received_VBD
a_DT
letter_NN
from_PIN
Andrx_NN
Pharmaceuticals_NN
LLC_NN
with_PIN
notification_NOMZ
that_TOBJ
Andrx_NN
has_VPRT [PEAS]
filed_VBN
an_DT
abbreviated_JJ
new_JJ
drug_NN
application_NOMZ
to_TO
market_VB
a_DT
generic_JJ
form_NN
of_PIN
Toprol-XL_JJ
extended_JJ
release_NN
tablets_NN
in_PIN
the_DT
50mg_JJ
dose_NN
which_WDT [WHOBJ]
it_PIT
intends_VPRT [SUAV]
to_TO
sell_VB
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
AstraZenecas_NN
patents_NN
listed_VBN [WZPAST]
in_PIN
the_DT
FDAs_NN
Orange_NN
Book_NN
,_,
the_DT
latest_JJ
of_PIN
which_WDT [PIRE]
expires_VPRT
in_PIN
March_NN
2008_CD
._.
Andrx_NN
claims_VPRT [PUBV]
that_THVC
each_QUAN
of_PIN
the_DT
listed_VBN
patents_NN
are_VPRT [BEMA]
invalid_PRED
and_CC
or_CC
not_XX0
infringed_VBN
._.
AstraZeneca_NN
is_VPRT
considering_VBG [PRIV]
whether_IN [WHCL]
to_TO
file_VB
a_DT
suit_NN
for_PIN
patent_NN
infringement_NOMZ
against_PIN
Andrx_NN
._.
Zestril_NN
lisinopril_NN
In_PIN
1986_CD
,_,
AstraZenecas_NN
predecessor_NN
company_NN
and_PHC
Merck_NN
&_CC
Co._NN
._.
Inc._NN
entered_VBD
into_PIN
licence_NN
agreements_NOMZ
under_IN
which_WDT
AstraZeneca_NN
was_VBD [PASS]
granted_VBN [SUAV]
the_DT
right_NN
to_TO
make_VB
,_,
use_VB
and_PHC
sell_VB
lisinopril_NN
Zestril_NN
,_,
in_PIN
return_NN
for_PIN
which_WDT [PIRE]
AstraZeneca_NN
agreed_VBD [SUAV] [PUBV]
to_TO
pay_VB
royalties_NN
to_PIN
Merck_NN
._.
In_PIN
April_NN
2002_CD
,_,
AstraZeneca_NN
commenced_VBD
arbitration_NOMZ
proceedings_GER
against_PIN
Merck_NN
under_IN
one_CD
of_PIN
the_DT
licence_NN
agreements_NOMZ
._.
In_PIN
the_DT
arbitration_NOMZ
,_,
AstraZeneca_NN
sought_VBD
repayment_NOMZ
of_PIN
approximately_RB
$_$
38m_CD
of_PIN
prior_JJ
royalty_NN
amounts_NN
and_CC
a_DT
prospective_JJ
reduction_NOMZ
in_PIN
the_DT
royalty_NN
rate_NN
going_VBG [WZPRES]
forward_RB
._.
The_DT
case_NN
was_VBD [PASS]
settled_VBN
in_PIN
May_POMD
2003_CD
._.
Under_IN
the_DT
settlement_NOMZ
agreement_NOMZ
,_,
Merck_NN
paid_VBD
$_$
37m_CD
to_PIN
AstraZeneca_NN
and_CC
the_DT
parties_NN
agreed_VBD [SUAV] [PUBV]
that_THVC
the_DT
royalty_NN
rate_NN
going_VBG [WZPRES]
forward_RB
would_PRMD
not_XX0
be_VB [PASS]
reduced_VBN
._.
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
investigation_NOMZ
In_PIN
June_NN
2003_CD
,_,
AstraZeneca_NN
announced_VBD [PUBV]
the_DT
settlement_NOMZ
of_PIN
a_DT
multi-year_JJ
investigation_NOMZ
into_PIN
US_FPP1
sales_NN
and_PHC
marketing_GER
practices_NN
for_PIN
Zoladex_NN
,_,
a_DT
treatment_NOMZ
for_PIN
prostate_NN
cancer_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
,_,
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
admitted_VBD [PUBV]
to_TO
having_VBG [PEAS]
violated_VBN
the_DT
Prescription_NOMZ
Drug_NN
Marketing_GER
Act_NN
by_PIN
providing_VBG
free_JJ
samples_NN
of_PIN
Zoladex_NN
to_PIN
physicians_NN
during_PIN
the_DT
period_NN
1993_CD
to_PIN
1996_CD
,_,
with_PIN
the_DT
understanding_GER
that_TOBJ
these_DEMO
physicians_NN
would_PRMD
bill_VB
Medicare_NN
for_PIN
reimbursement_NOMZ
._.
AstraZeneca_NN
also_RB
settled_VBD
,_,
without_PIN
admitting_VBG [PUBV]
liability_NOMZ
,_,
civil_JJ
claims_NN
involving_VBG [WZPRES]
allegations_NOMZ
that_TOBJ
the_DT
Company_NN
provided_VBD
inducements_NOMZ
to_PIN
physicians_NN
to_TO
purchase_VB
Zoladex_NN
and_CC
for_PIN
improperly_RB
setting_VBG
and_PHC
reporting_VBG [PUBV]
its_PIT
price_NN
._.
The_DT
total_JJ
payment_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
settlement_NOMZ
was_VBD
$_$
355m_CD
._.
This_DEMO
amount_NN
included_VBD
funds_NN
set_VBN [WZPAST]
aside_RB
to_TO
cover_VB
individual_JJ
settlement_NOMZ
agreements_NOMZ
with_PIN
the_DT
states_NN
involving_VBG [WZPRES]
related_JJ
claims_NN
._.
As_IN
previously_TIME
disclosed_VBN [PUBV]
by_PIN
the_DT
Company_NN
,_,
in_PIN
2002_CD
it_PIT
accrued_VBD
$_$
350m_CD
to_TO
cover_VB
these_DEMO
settlement_NOMZ
costs_NN
._.
The_DT
settlement_NOMZ
also_RB
provides_VPRT
for_PIN
a_DT
five-year_JJ
Corporate_JJ
Integrity_NOMZ
Agreement_NOMZ
with_PIN
the_DT
Office_NN
of_PIN
Inspector_NN
General_NN
OIG_NN
for_PIN
the_DT
Department_NOMZ
of_PIN
Health_NN
and_PHC
Human_NN
Services_NN
under_IN
which_WDT
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
is_VPRT [PASS]
required_VBN [SUAV]
,_,
among_PIN
other_JJ
obligations_NOMZ
,_,
to_TO
keep_VB
in_PIN
place_NN
its_PIT
current_JJ
compliance_NN
program_NN
and_CC
provide_VB
periodic_JJ
reports_NN
to_PIN
the_DT
OIG_NN
on_PIN
the_DT
status_NN
of_PIN
compliance_NN
activities_NOMZ
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
105_CD
31_CD
Assets_NN
pledged_VBN [SUAV]
,_,
commitments_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
continued_VBD
Average_JJ
wholesale_JJ
price_NN
class_NN
action_NOMZ
litigation_NOMZ
In_PIN
January_NN
2002_CD
,_,
AstraZeneca_NN
was_VBD [PASS]
named_VBN
as_IN
a_DT
defendant_NN
along_IN
with_PIN
24_CD
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
a_DT
class_NN
action_NOMZ
suit_NN
,_,
in_PIN
Massachusetts_NN
,_,
brought_VBD
on_PIN
behalf_NN
of_PIN
a_DT
putative_JJ
class_NN
of_PIN
plaintiffs_NN
alleged_VBN [PUBV]
to_TO
have_VB [PEAS]
overpaid_VBN
for_PIN
prescription_NOMZ
drugs_NN
as_CONJ
a_NULL
result_NULL
of_PIN
inflated_JJ
wholesale_JJ
list_NN
prices_NN
._.
The_DT
suit_NN
seeks_VPRT
to_TO
recover_VB
unspecified_JJ
damages_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
named_VBN
as_IN
a_DT
co-defendant_NN
with_PIN
various_JJ
other_JJ
pharmaceutical_JJ
manufacturers_NN
in_PIN
similar_JJ
suits_NN
filed_VBN [WZPAST]
in_PIN
seven_CD
other_JJ
states_NN
._.
Most_EMPH
of_PIN
these_DEMO
suits_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
with_PIN
the_DT
Massachusetts_NN
action_NOMZ
for_PIN
pre-trial_JJ
purposes_NN
pursuant_JJ
to_PIN
federal_JJ
multi-district_JJ
litigation_NOMZ
procedures_NN
._.
AstraZeneca_NN
believes_VPRT [PRIV]
that_THVC
it_PIT
has_VPRT
meritorious_JJ
defences_NN
to_PIN
all_QUAN
of_PIN
these_DEMO
claims_NN
._.
Notice_NN
of_PIN
state_NN
Attorneys_NN
General_NN
investigations_NOMZ
into_PIN
Medicaid_NN
price_NN
reporting_GER
In_PIN
December_NN
2003_CD
,_,
AstraZeneca_NN
received_VBD
notices_NN
from_PIN
multiple_JJ
US_FPP1
state_NN
Attorney_NN
General_NN
Offices_NN
requiring_VBG [SUAV] [WZPRES]
the_DT
Company_NN
to_TO
retain_VB
records_NN
relating_VBG [WZPRES]
to_PIN
Medicaid_NN
average_JJ
manufacturer_NN
price_NN
and_CC
best_JJ
price_NN
calculations_NOMZ
._.
Similar_JJ
notices_NN
have_VPRT [PEAS]
been_VBN [BYPA]
received_VBN
by_PIN
other_JJ
manufacturer_NN
codefendants_NN
in_PIN
the_DT
average_JJ
wholesale_JJ
price_NN
class_NN
action_NOMZ
litigation_NOMZ
referred_VBD
to_PIN
above_PLACE
._.
These_DEMO
notices_NN
appear_VPRT [SMP]
to_TO
have_VB [PEAS]
been_VBN [PASS]
intended_VBN [SUAV]
to_TO
address_VB
proposed_VBN [SUAV]
regulations_NOMZ
42_CD
CFR_NN
Part_NN
447.534_CD
h_NN
limiting_VBG [WZPRES]
a_DT
manufacturers_NN
record_NN
retention_NOMZ
obligations_NOMZ
for_PIN
government_NOMZ
price_NN
reporting_VBG [PUBV] [WZPRES]
data_NN
to_PIN
a_DT
three_CD
year_NN
period_NN
._.
The_DT
notices_NN
from_PIN
the_DT
Attorneys_NN
General_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
states_NN
are_VPRT
investigating_VBG
the_DT
accuracy_NN
of_PIN
AstraZenecas_NN
average_JJ
manufacturer_NN
price_NN
and_CC
best_JJ
price_NN
disclosures_NN
and_PHC
request_NN
that_TOBJ
the_DT
Company_NN
retains_VPRT
relevant_JJ
records_NN
beyond_IN
the_DT
three_CD
year_NN
limit_NN
of_PIN
the_DT
proposed_VBN [SUAV]
regulations_NOMZ
._.
US_FPP1
Federal_NN
Trade_NN
Commission_NN
Nexium_NN
investigation_NOMZ
As_IN
previously_TIME
disclosed_VBN [PUBV]
by_PIN
the_DT
Company_NN
,_,
in_PIN
January_NN
2003_CD
AstraZeneca_NN
received_VBD
a_DT
Civil_JJ
Investigative_NN
Demand_NN
from_PIN
the_DT
US_FPP1
Federal_NN
Trade_NN
Commission_NN
FTC_NN
for_PIN
certain_JJ
information_NOMZ
concerning_VBG [WZPRES]
AstraZenecas_NN
advertising_GER
and_PHC
marketing_GER
of_PIN
Nexium_NN
._.
In_PIN
July_NN
2003_CD
,_,
the_DT
FTC_NN
closed_VBD
its_PIT
investigation_NOMZ
without_PIN
action_NOMZ
._.
Retail_JJ
pharmacies_NN
drug_NN
purchasers_NN
actions_NOMZ
Since_OSUB
October_NN
1993_CD
,_,
several_QUAN
thousand_CD
retail_JJ
pharmacies_NN
and_CC
certain_JJ
retail_JJ
drug_NN
purchasers_NN
have_VPRT [PEAS]
commenced_VBN
purported_JJ
class_NN
actions_NOMZ
and_CC
individual_JJ
actions_NOMZ
in_PIN
various_JJ
federal_JJ
and_CC
state_NN
courts_NN
throughout_PIN
the_DT
US_FPP1
alleging_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
,_,
with_PIN
respect_NN
to_PIN
brand_NN
name_NN
prescription_NOMZ
drugs_NN
,_,
manufacturers_NN
and_PHC
wholesalers_NN
engaged_VBN [WZPAST]
in_PIN
discriminatory_JJ
pricing_GER
practices_NN
,_,
discriminatory_JJ
discounting_GER
and_PHC
rebate_NN
practices_NN
,_,
and_ANDC
or_CC
conspired_VBN
with_PIN
one_CD
another_DT
to_TO
fix_VB
prices_NN
and_CC
artificially_RB
maintain_VPRT [PUBV]
high_JJ
prices_NN
to_PIN
the_DT
plaintiffs_NN
in_PIN
restraint_NN
of_PIN
trade_NN
and_PHC
commerce_NN
._.
More_EMPH
than_PIN
20_CD
brand_NN
name_NN
prescription_NOMZ
drug_NN
manufacturers_NN
and_CC
eight_CD
wholesalers_NN
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
defendants_NN
in_PIN
some_QUAN
or_CC
all_QUAN
of_PIN
these_DEMO
suits_NN
._.
In_PIN
January_NN
2003_CD
,_,
an_DT
Alabama_NN
state_NN
court_NN
granted_VBD [SUAV]
AstraZenecas_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
consumer_NN
action_NOMZ
pending_VBG [WZPRES]
in_PIN
Alabama_NN
._.
The_DT
plaintiffs_NN
time_NN
to_TO
appeal_VB
that_DEMO
order_NN
of_PIN
dismissal_NN
has_VPRT [PEAS]
expired_VBN
._.
AstraZeneca_NN
has_VPRT [PEAS]
settled_VBN
or_CC
been_VBN [PASS]
dismissed_VBN
from_PIN
all_QUAN
of_PIN
the_DT
cases_NN
except_PIN
for_PIN
a_DT
retail_JJ
case_NN
pending_VBG [WZPRES]
in_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
consistently_RB
denied_VBN [PUBV]
liability_NOMZ
and_CC
continues_VPRT
to_TO
believe_VB [PRIV] [THATD]
it_PIT
has_VPRT
meritorious_JJ
defencesto_NN
the_DT
remaining_VBG
claims_NN
._.
Additional_JJ
government_NOMZ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
practices_NN
As_IN
is_VPRT [BEMA]
true_PRED
for_PIN
most_EMPH
,_,
if_COND
not_XX0
all_QUAN
,_,
major_JJ
prescription_NOMZ
pharmaceutical_JJ
companies_NN
operating_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
,_,
AstraZeneca_NN
is_VPRT [SPAU] [PASS]
currently_RB
involved_VBN
in_PIN
multiple_JJ
additional_JJ
US_FPP1
federal_JJ
and_CC
state_NN
criminal_JJ
and_PHC
civil_JJ
investigations_NOMZ
into_PIN
drug_NN
marketing_GER
and_PHC
pricing_GER
practices_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
received_VBN
subpoenas_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
Office_NN
in_PIN
Boston_NN
requesting_VBG [SUAV] [WZPRES]
production_NOMZ
of_PIN
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
sale_NN
and_PHC
promotion_NOMZ
of_PIN
Prilosec_NN
to_PIN
the_DT
New_NN
England_NN
Medical_NN
Center_NN
in_PIN
Boston_NN
._.
A_DT
separate_JJ
subpoena_NN
from_PIN
the_DT
same_JJ
office_NN
requests_NN
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
sale_NN
and_PHC
marketing_GER
of_PIN
products_NN
to_PIN
an_DT
individual_JJ
physician_NN
in_PIN
Worcester_NN
,_,
Massachusetts_NN
and_CC
certain_JJ
physicians_NN
and_PHC
entities_NOMZ
affiliated_VBN [WZPAST]
with_PIN
that_DEMO
physician_NN
._.
AstraZeneca_NN
has_VPRT [SPAU] [PEAS]
also_RB
received_VBN
a_DT
subpoena_NN
from_PIN
the_DT
Massachusetts_NN
Attorney_NN
Generals_NN
Office_NN
seeking_VBG [WZPRES]
documents_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
sale_NN
and_PHC
promotion_NOMZ
of_PIN
five_CD
products_NN
Prilosec_NN
,_,
Seroquel_NN
,_,
Rhinocort_NN
Aqua_NN
,_,
Toprol-XL_NN
and_PHC
Zestril_NN
within_PIN
Massachusetts_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
received_VBN
an_DT
investigative_JJ
demand_NN
from_PIN
the_DT
Missouri_NN
Attorney_NN
Generals_NN
Office_NN
seeking_VBG [WZPRES]
documents_NOMZ
and_PHC
information_NOMZ
relating_VBG [WZPRES]
to_PIN
agreements_NOMZ
with_PIN
drug_NN
retailers_NN
doing_VBG [WZPRES] [PROD]
business_NOMZ
within_PIN
Missouri_NN
._.
AstraZeneca_NN
is_VPRT
co-operating_VBG
with_PIN
these_DEMO
investigations_NOMZ
._.
It_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
predict_VB [PUBV]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
these_DEMO
investigations_NOMZ
,_,
which_WDT [SERE]
could_POMD
include_VB
the_DT
payment_NOMZ
of_PIN
damages_NN
and_CC
the_DT
imposition_NOMZ
of_PIN
fines_NN
,_,
penalties_NN
and_CC
administrative_JJ
remedies_NN
._.
General_NN
With_PIN
respect_NN
to_PIN
each_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
described_VBN
above_PLACE
,_,
other_JJ
than_PIN
those_DEMP
which_WDT
have_VPRT [PEAS]
been_VBN [PASS]
disposed_VBN
of_PIN [STPR]
,_,
we_FPP1
are_VPRT [BEMA]
unable_PRED
to_TO
make_VB
estimates_NN
of_PIN
the_DT
loss_NN
or_CC
range_NN
of_PIN
losses_NN
at_PIN
this_DEMO
stage_NN
._.
We_FPP1
also_RB
do_VPRT
not_XX0
believe_VB [PRIV]
that_THVC
disclosure_NN
of_PIN
the_DT
amount_NN
sought_VBN [WZPAST]
by_PIN
plaintiffs_NN
,_,
if_COND
that_DEMP
is_VPRT [PASS]
known_VBN [PRIV]
,_,
would_PRMD
be_VB [BEMA]
meaningful_PRED
with_PIN
respect_NN
to_PIN
those_DEMO
legal_JJ
proceedings_GER
._.
This_DEMP
is_VPRT [BEMA]
due_PRED
to_PIN
a_DT
number_NN
of_PIN
factors_NN
including_VBG [WZPRES]
for_CONJ
example_NULL
,_,
the_DT
stage_NN
of_PIN
the_DT
proceedings_GER
in_PIN
many_QUAN
cases_NN
trial_NN
dates_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
set_VBN
and_CC
overall_JJ
length_NN
and_PHC
extent_NN
of_PIN
legal_JJ
discovery_NN
,_,
the_DT
entitlement_NOMZ
of_PIN
the_DT
parties_NN
to_PIN
an_DT
action_NOMZ
to_TO
appeal_VB
a_DT
decision_NN
,_,
clarity_NOMZ
as_IN
to_PIN
theories_NN
of_PIN
liability_NOMZ
,_,
damages_NN
and_CC
governing_VBG
law_NN
,_,
uncertainties_NN
in_PIN
timing_NN
of_PIN
litigation_NOMZ
,_,
and_ANDC
the_DT
possible_JJ
need_NN
for_PIN
further_JJ
legal_JJ
proceedings_GER
to_TO
establish_VB [PRIV]
the_DT
appropriate_JJ
amount_NN
of_PIN
damages_NN
,_,
if_COND
any_QUAN
._.
However_CONJ
,_,
although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
or_CC
investigations_NOMZ
referred_VBD
to_PIN
in_PIN
this_DEMO
Note_NN
31_CD
to_PIN
the_DT
Financial_NN
Statements_NOMZ
,_,
we_FPP1
do_VPRT
not_XX0
expect_VB [PRIV]
them_TPP3
to_TO
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
or_CC
profitability_NOMZ
._.
